Intravenous beta-blocker therapy in ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention is not associated with benefit regarding short-term mortality: a Swedish nationwide observational study

EuroIntervention 2017;13:e210-e218 published online February 2017 published online e-edition June 2017. DOI: 10.4244/EIJ-D-16-01021

Moman Mohammad
Moman A. Mohammad1, MD; Pontus Andell1, MD, PhD; Sasha Koul1, MD, PhD; Liyew Desta2, MD, PhD; Tomas Jernberg3, MD, PhD; Elmir Omerovic4, MD, PhD; Jonas Spaak2, MD, PhD; Ole Fröbert5, MD, PhD; Jens Jensen6, MD, PhD; Thomas Engstrøm7, MD, PhD; Claes Hofman-Bang2, MD, PhD; Hans Persson2, MD, PhD; David Erlinge1*, MD, PhD
1. Department of Cardiology, Clinical Sciences, Lund University, Skane University Hospital, Lund, Sweden; 2. Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden; 3. Department of Medical Epidemiology and Biostatist

Aims: Our aim was to investigate the impact of intravenous (IV) beta-blocker therapy on short-term mortality and other in-hospital events in patients with ST-segment elevation myocardial

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

adjunctive pharmacotherapyclinical trialst-segment elevation myocardial infarction (stemi)
Coronary interventionsSTEMIAdjunctive pharmacotherapy
Read next article
Percutaneous intervention in chronic total coronary occlusions caused by in-stent restenosis: procedural results and long-term clinical outcomes in the TORO (Spanish registry of chronic TOtal occlusion secondary to an occlusive in-stent RestenOsis) multicentre registry

Latest news